Zymeworks Inc. (ZYME)
| Market Cap | 1.83B +46.0% |
| Revenue (ttm) | 37.13M -69.8% |
| Net Income | -149.99M |
| EPS | -2.01 |
| Shares Out | 70.96M |
| PE Ratio | n/a |
| Forward PE | 14.98 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 491,135 |
| Open | 25.28 |
| Previous Close | 25.26 |
| Day's Range | 25.28 - 26.34 |
| 52-Week Range | 16.00 - 31.34 |
| Beta | 1.17 |
| Analysts | Strong Buy |
| Price Target | 41.21 (+59.79%) |
| Est. Earnings | Nov 5, 2026 |
About ZYME
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead pr... [Read more]
Financial Performance
In 2025, Zymeworks's revenue was $105.97 million, an increase of 38.87% compared to the previous year's $76.30 million. Losses were -$81.13 million, -33.88% less than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for ZYME stock is "Strong Buy." The 12-month stock price target is $41.21, which is an increase of 59.79% from the latest price.
News
Zymeworks price target raised to $34 from $32 at Truist
Truist raised the firm’s price target on Zymeworks (ZYME) to $34 from $32 and keeps a Buy rating on the shares as part of a broader research note previewing Q3…
Zymeworks reinstated with a Buy at TD Cowen
TD Cowen analyst Yaron Werber reinstated coverage of Zymeworks (ZYME) with a Buy rating and $34 price target after the company closed the Theravance acquisition. The firm views the Theravance…
Zymeworks price target raised to $39 from $38 at Citi
Citi raised the firm’s price target on Zymeworks (ZYME) to $39 from $38 and keeps a Buy rating on the shares. The firm says the close of the Theravance deal…
LifeSci flags Yupelri as a key growth driver after Zymeworks’ Theravance deal
LifeSci Capital notes Zymeworks (ZYME) announced the completion of the Theravance Biopharma (TBPH) acquisition. Yupelri is expected to be immediately accretive to revenue and cash flow, with a mid-tee...
Zymeworks Transcript: M&A announcement
The Theravance acquisition is closed, adding YUPELRI cash flows, an R&D portfolio, and Irish tax attributes. Non-recourse financing supports the deal; base-case returns are mid-teens IRR, excluding several potential upside sources.
Zymeworks Press release: M&A announcement
Zymeworks issued a press release on September 28, 2026, disclosing material business information to investors.
Zymeworks Slides: M&A announcement
Zymeworks has posted slides in relation to its latest quarterly earnings report, which was published on September 28, 2026.
Zymeworks sees FY26 revenue $278M-$292M, consensus $304.04M
With the completion of the Theravance Biopharma acquisition and the receipt of the U.S. FDA approval of Ziihera for first-line HER2-positive advanced gastroesophageal adenocarcinoma on August 25, 2026...
Zymeworks announces financial impact of Theravance Biopharma acquisition
The acquisition is expected to provide Zymeworks (ZYME) with meaningful and immediate incremental revenue and operating cash flow following closing, including: Mid-teens base-case IRR, supported prima...
Zymeworks Announces Updated 2026 Financial Guidance and Final Transaction Details Following Theravance Biopharma Acquisition
VANCOUVER, British Columbia, Sept. 28, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pi...
Zymeworks Completes Acquisition of Theravance Biopharma
VANCOUVER, British Columbia, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pip...
Zymeworks initiated with an Outperform at Wolfe Research
Wolfe Research initiated coverage of Zymeworks (ZYME) with an Outperform rating.
Zymeworks Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
FDA approval of zanidatamab in HER2-positive gastric cancer establishes a new standard of care and drives significant royalty and milestone potential. The pipeline is advancing with multiple phase III readouts and innovative trispecific and ADC programs, while disciplined capital allocation and strategic partnerships, including the Theravance acquisition, support long-term growth.
Zymeworks Transcript: Wells Fargo 21st Annual Healthcare Conference
Recent FDA approval for zanidatamab in GEA has set a new standard of care and boosted sales projections. The business model integrates royalty growth, strategic acquisitions, and R&D, with flexible capital allocation and a focus on sustainable, risk-adjusted cash flows. Theravance acquisition and a robust pipeline further diversify growth opportunities.
Zymeworks price target raised to $33 from $31 at JPMorgan
JPMorgan raised the firm’s price target on Zymeworks (ZYME) to $33 from $31 and keeps an Overweight rating on the shares. The firm updated the company’s model. Published first on…
Zymeworks price target raised to $38 from $37 at Citi
Citi raised the firm’s price target on Zymeworks (ZYME) to $38 from $37 and keeps a Buy rating on the shares after the company and its partners received FDA approval…
Zymeworks price target raised to $55 from $51 at H.C. Wainwright
H.C. Wainwright raised the firm’s price target on Zymeworks (ZYME) to $55 from $51 and keeps a Buy rating on the shares after the company’s partner Jazz Pharmaceuticals announced FDA…
Zymeworks says partner Jazz receives FDA approval for Ziihera regimens
Zymeworks (ZYME) announced that its partner, Jazz Pharmaceuticals, has received U.S. Food and Drug Administration approval for two Ziihera-containing regimens for the first-line treatment of adults wi...
Zymeworks price target raised to $44 from $40 at B. Riley
B. Riley analyst Mayank Mamtani raised the firm’s price target on Zymeworks (ZYME) to $44 from $40 and keeps a Buy rating on the shares. Zymeworks’ pending Theravance (TBPH) combination…
Citi adds ‘upside 90-day catalyst watch’ on Zymeworks in FDA decision
Citi added an “upside 90-day catalyst watch” on Zymeworks (ZYME) while keeping a Buy rating on the shares with a $37 price target The stock can rally into zanidatamab’s HER2-positive…
Zymeworks price target raised to $32 from $31 at Truist
Truist analyst Gregory Renza raised the firm’s price target on Zymeworks (ZYME) to $32 from $31 and keeps a Buy rating on the shares. Zymeworks enters a key 2H26 catalyst…
Zymeworks price target lowered to $46 from $47 at Stifel
Stifel lowered the firm’s price target on Zymeworks (ZYME) to $46 from $47 and keeps a Buy rating on the shares.
Zymeworks price target raised to $40 from $37 at Wells Fargo
Wells Fargo raised the firm’s price target on Zymeworks (ZYME) to $40 from $37 and keeps an Overweight rating on the shares. No surprises from Thursday’s update, with focus on…
Zymeworks reports Q2 EPS (62c), consensus (55c)
Reports Q2 revenue $4.6M, consensus $10.90M. The decrease in revenue was driven mainly by the absence of significant non-recurring collaboration revenue recognized in the prior year, as well as contin...
Zymeworks Provides Corporate Update and Reports Second Quarter 2026 Financial Results
August 25, 2026 U.S. PDUFA target action date for zanidatamab has potential to unlock a $250 million U.S. approval milestone and up to $190 million in potential additional global regulatory milestones...